Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 3Sarcoma 2Plasma cell 2Head & Neck 2Gastrointestinal 2Dermatologic 2CNS 2Breast 2Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 20Triple Negative Breast Neoplasms 14Ovarian Neoplasms 7Melanoma 7Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Neoplasm Metastasis 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Sarcoma 3Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Liver Neoplasms 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

pembrolizumab 7Cyclophosphamide 7Surveys and Questionnaires 4Filgrastim 4aldesleukin 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Nivolumab 3Methods 3Flow Cytometry 3Early Intervention, Educational 3valspodar 2sargramostim 2fludarabine 2atezolizumab 2Therapeutics 2Stem Cell Factor 2Sirolimus 2Methylprednisolone 2Melphalan 2Ipilimumab 2Interleukin-2 2Immunologic Techniques 2Exercise 2Etoposide 2Epoetin Alfa 2Educational Status 2Drug Therapy 2Data Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Ipilimumab × Breast × Clear all
NCT03058289 2025-02-27

IT-01

Intensity Therapeutics, Inc.

Phase 1/2 Completed
111 enrolled 21 charts
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Lytix Biopharma AS

Phase 1 Completed
80 enrolled
BreastDermatologicHead & NeckLymphoid

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡